In gene therapy, promoters act as vital “on/off” switches, dictating whether a therapeutic gene is active and to what extent. While delivery vehicles such as adeno-associated viruses (AAVs) can bring the therapeutic cargo to its intended destination, promoters provide an additional layer of specificity and safety by restricting gene expression to particular cell types or tissues and by controlling the level of gene expression. Often, natural promoters suffer from low expression specificity and can provoke adverse immune responses, while natural tissue-specific promoters typically display low activity. The development of new synthetic gene promoters designed for the precise control of transgene expression has the potential to enhance the safety and efficacy of gene therapies in line with evolving regulatory expectations.
Read how SynGenSys is bringing synthetic promoter technology to enhance gene therapy specificity, efficacy, and safety in this article published on 6th January 2026 with Technology networks at Designing Synthetic Gene Promoters for Gene Therapy Success | Technology Networks
